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’INTRODUCTION
A large body of evidence indicates that tumor hypoxia has a
negative prognosis predictive value for solid tumor progression,
likeliness of metastasis and tumor prognosis, likeliness of metas-
tasis,andoverallsurvival.
1 3Inaddition,tumorcellhypoxiahasa
negative eﬀect on anticancer treatment because of resistance to
radiation.
4,5 Accordingly, it is important to identify and localize
tumor hypoxia in the management and treatment of cancer
patients. Contrary to invasive methods based on the oxygen
electrode system
6 to determine the oxygenation distribution in
the tumor, noninvasive ones
7,8 are based on imaging using
radiolabeled (
123I,
124I,
125I,
18F,
60Cu,
62Cu,
64Cu) tracers
1 6 (Figure 1), preferably
18F-labeled 2-nitroimidazoles. The
tracer's primary cellular uptake results from diﬀusion and parti-
tion-based retention in lipophilic tissue.
The2-nitroimidazole(azomycin)-basedtracersarethoughtto
be reduced in hypoxic cells to reactive intermediates, which bind
to macromolecular components. Thus, they tend to be accumu-
lated in sites of hypoxia and can be used for imaging purposes
with single-photon-emission tomography (SPECT) and posi-
tronemissiontomography(PET),thelatterbeingthemethodof
choice. Indeed, a number of radiotracers for viable hypoxic cells
insolidtumorsarebeingevaluatedclinically.
9Theinitialimaging
studies of tumor hypoxia used iodine-123-labeled iodoazomycin
arabinoside (α-IAZA, 4) with SPECT
10 and ﬂuorine-18-labeled
ﬂuoromisonidazole (FMISO, 1) with PET.
11,12 Recently,
[
18F]ﬂuoroerythronitroimidazole ([
18F]FETNIM, 2) was stu-
died as a hypoxia imaging agent.
13 The copper complex copper-
(II) diacetylbis(N
4-methylthiosemicarbazone) (Cu-ATMS, 3)
labeled with the positron emitter
60Cu,
62Cu, or
64Cu is another
promising hypoxic imaging agent under evaluation.
14
More recently, the ﬂuoroazomycin arabinoside α-[
18F]FAZA
(5) has been studied extensively alone and relative to FMISO.
15
It was found that α-[
18F]FAZA and [
18F]FMISO are taken up
selelctively in vitro and in vivo in hypoxic cells.
16 Machulla et al.
observed that α-[
18F]FAZA shows biokinetics superior to
that of [
18F]FMISO and is, thus, a promising PET tracer for
visualization of solid tumor hypoxia. The
125I- and
124I-labeled
Figure 1. Radiolabeled tracers for imaging hypoxia.
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ABSTRACT: 2-Nitroimidazole was silylated using hexaethyldisilazane and then
reacted with 1-O-acetyl derivatives of D-arabinose, D-ribose, and D-galactose in
acetonitrile at mild temperatures ( 20 C to rt), catalyzed by triethylsilyl triﬂate
(Vorbr€ uggenconditions).Theα-anomerwasformedintheformercaseandtheβ-
anomersinthelattertwocases(highly)selectively.When D-arabinoseand D-ribose
were silylated with tert-butyldiphenylsilyl chloride in pyridine at the hydroxyl
groups at C-5 and acetylated at the other ones in a one-pot reaction, mixtures of
anomeric 1-O-acetyl derivatives were obtained. These were coupled by the Vorbr€ uggen method and then deblocked at C-5 and
tosylated to give precursors for tracers to image hypoxia in four steps without using Hg(CN)2 necessary for other methods. The
Vorbr€ uggen conditions enable a shorter route to azomycin nucleoside analogues than the previous coupling procedures.8160 dx.doi.org/10.1021/jo200727k |J. Org. Chem. 2011, 76, 8159–8167
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2-nitroimidazole β-D-galactosides 6 were used to image tumor
hypoxia in mice.
17 A st h eu p t a k eo fα-[
18F]FAZA is diﬀusion
controlled and its renal clearance is rapid, it is still attractive to
prepare other 2-nitroimidazole nucleosides and evaluate them as
precursors for tracers to image hypoxia. To improve the tumor/
backgroundratiooftracers,theiractivetransportbycellulartransport
systems such as nucleoside transporters could be exploited. Emami
et al. have established a yeast system for testing the transport of
ﬂuoroazomycin nucleosides by four nucleoside transporters, which
might help to ﬁnd better tracers than α-[
18F]FAZA.
18
Tracer 5 most favored at present for imaging hypoxia is
prepared from precursor α-7 by a substitution reaction (SN2)
with cyclotron-generated
18F
  in combination with Kryptoﬁx
2.2.2, followed by base-catalyzed removal of acetyl groups
and HPLC puriﬁcation (Scheme 1). The 2-nitroimidazole
nucleosides underlying tracers 4, 5, and 6 are formed by a
K€ onigs Knorr reaction of 2-nitroimidazole or in some cases
its trimethylsilylated species in acetonitrile at 50 60 Cw i t ha
benzoyl-oranacetyl-protected D-1-bromofuranoseor D-1-bromo-
pyranose derivatives of D-arabinose or D-galactose, respec-
tively. Normally, excess Hg(CN)2 (2.2 equiv), sometimes in
combination with SnCl4, was used as a catalyst.
19 21 This
method was used by Schneider et al. to prepare a number of
2-nitroimidazole nucleosides, two of which were converted to
radioiodinated tracers. When we started this project to prepare
known and new precursors for tracers to image hypoxia, we
decided to search for an alternative to the K€ onigs Knorr
procedure not involving metal salts, especially toxic Hg(CN)2.
Ideally,themethodshoulduseeasilyaccessiblestartingmaterials
with an adequately silylated hydroxyl group at C-5 and acetyl
groups for the other hydroxyls of furanoses derived from D-
arabinose and D-ribose. The 2-nitroimidazole nucleosides then
formed would yield products which could be deprotected and
tosylated at C-5 to give the desired precursors. Additionally, the
desilylated products could be transformed to the ﬂuorides and
deblocked to give the cold ﬂuoro standards.
’RESULTS AND DISCUSSION
Preparation of Triethylsilylated 2-Nitroimidazole and
2-Nitroimidazole Nucleosides Derived from D-Arabinose.
We envisaged to test the Vorbr€ uggen method for the coupling
first.
22 It is based on the coupling of trimethylsilylated hetero-
cyclic bases with protected sugar derivatives with an acetoxy or
methoxy group at C-1 in CH3CN, CH2Cl2, or 1,2-C2H4Cl2,
catalyzed by trimethylsilyl triflate. Surprisingly, it has never been
used for the synthesis of azomycin nucleosides. The solubility of
2-nitroimidazole is very low in allcommonsolvents, especially at
rt or below, and even trimethylsilylation with hexamethyldisila-
zane/(NH4)2SO4 in pyridine had only a marginal effect on its
solubility. Therefore, we decided to use triethylsilylation to
increase the solubility further, which proved to be critical for
our success.
We accessed hexaethyldisilazane, a known
23 but diﬃcult to
prepare reagent, easily from (triethylsilyl)amine
24 and chloro-
triethylsilane in the presence of a catalytic amount of triethylsilyl
triﬂate (TfOTES) in dry toluene in 79% yield (Scheme 2).
Initially, we reﬂuxed a mixture of 2-nitroimidazole (NI) and
4 6 equiv of hexaethyldisilazane and a catalytic amount of
(NH4)2SO4 in pyridine until the reaction mixture was homo-
geneous. However, later we found that 2 equiv was suﬃcient for
silylation within 30 min and that the catalyst could be omitted.
Removal of volatile components left NI-TES (2-nitro-
1-(triethylsilyl)imidazole) as a crystalline product, which was
useddirectly.Surprisingly,(triethylsilyl)aminedidnotsilylateNI
in reﬂuxing pyridine.
In the ﬁrst place, we wanted to couple NI-TES with a suitable
D-arabinofuranose derivative containing a silyl-proteced C-5
hydroxyl group. Thus, a mixture of D-arabinose and tert-butyldi-
phenylsilyl chloride (TBDPSCl) in pyridine was allowed to
warm in the cooling bath from  20 C to rt for 18 h. Stirring
was continued for 6 h after the addition of acetic anhydride.
Aqueous workup and ﬂash chromatography furnished a mixture
of anomeric acetates (α:β = 60:40) in an admixture with
impurities as a syrup in 71% yield (Scheme 3). The predominat-
ing α-anomer crystallized and was fully characterized. Recently,
Chatterjee et al. isolated the 5-O-TBDPS-protected D-arabinose
and then acetylated it in an overall yield of 46%.
25 The coupling
experiments were performed with the anomeric mixture 14.
Under optimized conditions, a mixture of NI-TES and 14 in
CH3CN was cooled to  20 C, and 1 equiv of a 1 M solution of
TfOTES in 1,2-C2H4Cl2 was added dropwise. Stirring was
continued while the reaction mixture was allowed to warm to
 8 C within 3 h. Extractive workup and ﬂash chromatography
furnished the α-nucleoside
26 α-15 in 72% yield beside some
starting material and a trace of the β-anomer detected by TLC,
which was not isolated (Scheme 3). Anticipating later results,
α-15 was converted in two steps into precursor α-7. As the
Scheme 1. Synthesis of α-[
18F]FAZA Scheme 2. Synthesis of Hexaethyldisilazane and Its Use for
the Triethylsilylation of 2-Nitroimidazole
Scheme 3. Preparation of D-Arabinofuranose Derivative 14
and Its Coupling with NI-TES by the Vorbr€ uggen Method8161 dx.doi.org/10.1021/jo200727k |J. Org. Chem. 2011, 76, 8159–8167
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β-nucleosideβ-15wasalsoneeded,CH3CNwasreplacedby1,2-
C2H4Cl2,hopingtoincreasetheamountoftheβ-anomer.When
NI-TMS and the mixture of α- and β-14 were coupled in 1,2-
C2H4Cl2 with0.5 equiv of TfOTMS as a catalyst for 4 hat rt, the
yield for β-15 was 13% and that for α-15 16%. The yield of β-15
increased to 31%, when the coupling was modiﬁed (NI-TES,
50 C, 1.2 equiv of TfOTES, 2 h). The low and irreproducible
yields in this halogenated solvent were attributed to the unsa-
tisfactory solubility of NI-TES. Although the β-nucleoside was
formed preferentially, the method was not suitable for the
preparation of relevant amounts of β-7. The preferred formation
of the α-anomer is attributed to the neighboring group eﬀect by
the 2-acetoxy group, which is β-orientated.
22 However, the
formation of the β-anomer results very likely from the inter-
mediacy of a nitronate ester as suggested by others.
19
Preparation of 2-Nitroimidazole Nucleosides Derived
from D-Ribose. To broaden the scope of the method, we studied
the reaction of NI-TES with D-ribose and D-galactose derivatives
catalyzed by silyl triflates as well. First, D-ribose was silylated and
acetylated in a one-pot reaction in the same way as D-arabinose,
except that the acetylation was performed at 50 C, to give a
mixture(54:46)ofα-andβ-triacetate17whichcouldbeseparated
by flash chromatography (Scheme 4). Each anomer was reacted
with NI-TES in CH3CN catalyzed by 1 equiv of TfOTES. When
the reaction mixture was allowed to warm from  20 to  8 C
within2h,triacetateβ-17furnisheda72%yieldofβ-nucleosideβ-
18 and a trace of the α-nucleoside as detected by TLC. Similarly,
α-triacetate yielded 87% of the β- and a trace of the α-nucleoside
(20Ctortwithin2h).Asthetwoanomersreactedsimilarly,their
separation was not worthwhile. In the latter case, the influence of
the temperature on the outcome was studied. Below  20 C,
couplingdidnottakeplace;between 10and 5Catareaction
time of 4 h, a mixture of nucleosides resulted (β-18:α-18 =2 : 1 ,
combined yield 60%). No nucleoside was formed in 1,2-C2H4Cl2
under a varietyof conditions. Analternative for the preparationof
azomycin nucleosides derived from D-ribose is the coupling of
commercially available acetate 19 (Scheme 5). It was found
that TfOTMS was a better catalyst than TfOTES with this sub-
strate. When the Vorbr€ uggen coupling was effected in CH3CN
( 20 to  10 C, 1.2 equiv of TfOTMS), a 72% yield of nucleo-
side β-20 resulted. However, when the same reaction was per-
formed for 30 min at rt, a separable mixture (α-20,4 2 % ;β-20,
31%) of nucleosides was obtained. These results underlined the
necessity to control the reaction temperature carefully and use
CH3CNasthesolventofchoiceforagoodyield.Forcomparison,
Prisbe et al. found that NI and 19 gave a 61% yield of α-20,w h e n
treatedwith2equivofSnCl4andHg(CN)2inCH3CNat60C.
19
Toobtainβ-20in68%yield,acetate19hadtobefirstconvertedto
thecorrespondingbromidebybubblingHBrthroughasolutionof
it and then reacting it analogously to before with 2 equiv of
Hg(CN)2 without SnCl4. The predominant formation of the
β-anomer here is again attributed to the neighboring group effect
(2-acyloxy group is α)a n dt h eα-anomer to the possible involve-
ment of a nitronate ester.
Preparationof2-NitroimidazoleNucleosideDerivedfrom
D-Galactose.Atlast,commerciallyavailableβ-D-galactopyranose
pentaacetate was converted to the 2-nitroimidazole nucleoside
β-22 in high yield(92%) in CH3CN under very mild conditions,
whenthereactionmixture wasstirred for1hat0Cand1hatrt
(Scheme 6). For comparison, the coupling of acetobromo-α-D-
galactose with 2-nitroimidazole catalyzed by 2.5 equiv of Hg-
(CN)2for23hat40CinalargevolumeofCH3CNyielded88%
of the desired β-nucleoside.
21
Conversion of 2-Nitroimidazole Nucleosides Derived
from α- and β-D-Arabinose and D-Ribose to (Putative) Pre-
cursors for Tracers To Image Hypoxia. The precursor α-7 for
the preparation of α-[
18F]FAZA can be accessed easily from
silylated nucleoside α-15. It was deblocked with HF generated
in situ from KF/benzoic acid
27 in refluxing CH3CN in 90% yield
and tosylated to give precursor α-7
28 in 94% yield, first prepared
by Wiebe et al. (Scheme 7). This sequence comprises only four
steps and is the shortest synthesisof precursor α-7, starting from
D-arabinose.
The synthesis of β-7 was ﬁrst accomplished also by Wiebe
et al., starting from 1-β-(D-ribofuranosyl)-2-nitroimidazole
Scheme 4. Preparation and Coupling of Protected D-Riboses
17
Scheme 5. Coupling of 1-O-Acetyl-2,3,5-tri-O-benzoyl-α-D-
ribofuranose with NI-TES by the Vorbr€ uggen Method
Scheme 6. Coupling of 1,2,3,4,6-Penta-O-acetyl-β-D-galacto-
pyranose with NI-TES by the Vorbr€ uggen Method8162 dx.doi.org/10.1021/jo200727k |J. Org. Chem. 2011, 76, 8159–8167
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obtained by debenzoylation of D-ribose derivative β-20.
21d,27
The hydroxyl groups at C-50 and C-30 were protected with the
30,50-O,O-(1,1,3,3-tetraisopropyldisiloxanylidene) group, and
the conﬁguration of the free hydroxyl at C-20 was inverted by
substituting the triﬂate with tetrabutylammonium acetate.
27
Then the disiloxanylidene group was removed, and the diol
was monotosylated and acetylated to give β-7. We thought that
we could shorten the lengthy synthesis by starting from a β-D-
ribose derivative already containing the disiloxanylidene group
(Scheme8).Thus, D-ribose was silylated andacetylated ina one-
pot reaction in the same way as the TBDPS-protected analogue
17 was prepared. The crude anomeric mixture containing
impurities (47% yield) of α- and β-24 (74:19) was coupled with
NI-TESinCH3CNwith1equivofTfOTESat0Cfor45minto
give separable nucleosides (β-25, 30%; α-25, 32%). Unfortu-
nately, lowering the reaction temperature to  10 C favored the
α-anomer even more (β-25, 16%; α-25, 32%). However, the
yield of the desired β-anomer was too low to pursue this
approach any further. The putative precursor derived from β-
D-ribose was accessed from silyl-protected β-18 (Scheme 9). It
was selectively deblocked at C-50 and tosylated to furnish
precursor β-27. Analogously, the α-anomer was prepared from
α-18, which was either directly accessible by coupling by the
Vorbr€ uggen method or accessible from tribenzoate α-20
(Scheme 10). Transesteriﬁcation with MeOH/MeONa gave
triolnucleosideα-28inanadmixturewithanunknownimpurity,
possibly of structure 29, already reported
19 by Prisbe et al. The
twocompoundscouldnotbeseparatedbyﬂashchromatography,
but easily after monosilylation with TBDPSCl. The silylated diol
α-30 formed was acetylated to give nucleoside α-18. The
seemingly obvious direct conversion of α-28 to the precursor
α-27 by monotosylation followed by acetylation did not work as
tosylation could not be conducted selectively, but produced a
ditosylate preferentially.
’CONCLUSIONS
Our results unambiguously establish that 1-O-acetyl-D-pen-
toses and D-galactose pentaacetate and triethylsilylated 2-nitro-
imidazole can be coupled in acetonitrile using TESOTf
(Vorbr€ uggen method) to give 2-nitroimidazole nucleosides.
The anomeric ratio of the products is delicately inﬂuenced by
the substrate structure and the reaction temperature. This
approach is an attractive alternative to protocols based on excess
Hg(CN)2aloneorincombinationwithSnCl4forcoupling.50-O-
TBDPS nucleosides can be desilylated and tosylated easily to
furnish precursors for tracers to image hypoxia.
Scheme 7. Transformation of Azomycin Nucleoside α-15
into Precursor α-7
Scheme 8. Preparation of 3,5-O,O-(1,1,3,3-Tetra-
isopropyldisiloxanylidene)-Protected D-Riboses 24 and Their
Coupling with NI-TES by the Vorbr€ uggen Method
Scheme 9. Preparation of Putative Precursors α- and β-27
Scheme 10. Conversion of Tribenzoate α-20 to the Silylated
Diacetate α-188163 dx.doi.org/10.1021/jo200727k |J. Org. Chem. 2011, 76, 8159–8167
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’EXPERIMENTAL SECTION
1Hand
13C(J-modulated;additionally,non-J-modulatedspectrawere
recorded of compounds containing 2-nitroimidazole) NMR spectra
were measured at 300 K at 400.13 and 100.61 MHz, respectively. All
chemical shifts (δ) are given in parts per million. They were referenced
either to residual CHCl3 (δH 7.24)/toluene-d8 (CHD2, δH 2.09)/
CD3OD (CHD2, δH 3.31)/DMSO-d6 (CHD2, δH 2.50) or CDCl3 (δC
77.00)/toluene-d8(CD3,δC21.04)/CD3OD(CD3,δC49.00)/DMSO-
d6(CD3,δC39.50).IRspectraofﬁlmsonasilicondiskwererecordedon
anFT-IRspectrometer.
29Opticalrotationsweremeasuredat20Cona
polarimeter in a 1 dm cell. Melting points are uncorrected.
Flash (column) chromatography was performed with silica gel 60
(230 400 mesh) andmonitored by TLC, carried out on0.25 mm thick
plates, silica gel 60 F254. Spots were visualized by UV and/or by dipping
the plate into a solution of (NH4)6Mo7O2434H2O (23.0 g) and
Ce(SO4)234H2O (1.0 g) in 10% aqueous H2SO4 (500 mL), followed
by heating with a heat gun.
General Procedure A: Triethylsilylation of 2-Nitroimida-
zole. A mixture of 2-nitroimidazole (0.113 g, 1 mmol), hexaethyldisi-
lazane (0.491 g, 2 mmol, 2equiv), and drypyridine (2mL) was refluxed
for 30 min. The solution was cooled (silylated compound crystallized),
and volatile components were removed by bulb to bulb distillation
(70 75 C, 0.4 mbar) to leave brown crystalline 1-(triethylsilyl)-
2-nitroimidazole, which was used immediately without further
purification.
General Procedure B: Desilylation of 2-Nitroimidazole
Nucleosides with a TBDPSO Group at C-50. A mixture of the
nucleoside (0.50 mmol),KF(0.407 g, 3.50 mmol, 7equiv), and benzoic
acid(0.427g,3.50mmol,7equiv)indryCH3CN(11.5mL)washeated
at 75 C for 7 h (monitored by TLC).
27 The mixture was then cooled,
filtered, and concentrated under reduced pressure.
General Procedure C: Tosylation of 2-Nitroimidazole Nu-
cleosidesDerivedfrom D-PentoseswithaFree50-OHGroup.
A solution of p-toluenesulfonyl chloride (0.521 g, 2.73 mmol, 3 equiv)
andnucleosidewithafree50-OHindrypyridine(5mL)waskeptfor18
ha t4C (TLC, hexanes/EtOAc, 1:2). Then water (10 mL) and 2 M
HCl (10 mL) were added, and the mixture was extracted with EtOAc
(3   10 mL). The combined organic layers were washed with saturated
aq NaHCO3 (10 mL) and water (10 mL), dried (Na2SO4), and
concentrated under reduced pressure.
Hexaethyldisilazane (10). Triethylsilyl triflate (0.2 mL) was
added to a stirred solution of (triethylsilyl)amine (8)
24 [9.66 g, 73.6
mmol, 3.2 equiv; 70 80 C, 80 mmHg; 75% yield; nD
20 1.4250 (lit.
24 bp
134 C, nD
20 1.4267)] and chlorotriethylsilane (3.47 g, 3.86 mL, 23
mmol) in dry toluene (40 mL) at 0 C. Precipitation of NH4Cl started
immediately. After being stirred for 2 h at rt, the mixture was filtered
through Celite. The filtrate was concentrated under reduced pressure,
andtheresiduewasbulbtobulbdistilled(70 75C,0.5mbar;lit.
23bbp
100 C, 1 mmHg) to give 10 (8.92 g, 79%) as a colorless liquid: nD
27
1.4502;
1H NMR (400.1 MHz, toluene-d8) δ 0.98 (t, J = 8.0 Hz, 18H),
0.53(q,J=8.0Hz,12H), 0.29(brs,1H,NH);
13CNMR(100.6MHz,
toluene-d8) δ 8.4, 8.0.
1,2,3-Tri-O-acetyl-5-O-(tert-butyldiphenylsilyl)-α-and1,2,
3-Tri-O-acetyl-5-O-(tert-butyldiphenylsilyl)-β-D-arabinofur-
anose (α- and β-14). A mixture of D-arabinose (0.751 g, 5 mmol) in
drypyridine(10mL)wascooledto 20Cunderargon,andTBDPSCl
(t-BuPhe2SiCl) (1.374 g, 1.30 mL, 5 mmol) was added. The reaction
mixture was allowed to slowly warm to rt in the cooling bath overnight
(TLC,hexanes/EtOAc,2:1).AfteradditionofAc2O(4mL)thesolution
was stirred at rt for 6 h. Volatile components were removed under
reduced pressure and the residue taken up with water (10 mL) and 2 M
HCl (10 mL). The mixture was extracted with CH2Cl2 (3   10 mL).
The combined organic layers were washed with saturated aq NaHCO3
(10 mL) and water (10 mL), dried (Na2SO4), and concentrated under
reduced pressure. The crude product was purified by flash chromatog-
raphy (hexanes/EtOAc, 2:1, Rf 0.63) to give the mixture of anomeric
acetates (1.83 g, 71%) as an oil,
25 α:β = 60:40 (by
1H NMR), [α]D
20
+19.3 (c 3.0, acetone). After a few months crystals of the α-anomer
formed in the oil. They were collected after the oil was dissolved in
i-Pr2O/hexanes and recrystallized (i-Pr2O/hexanes) to give the homo-
geneous α-anomer: mp 92 93 C; [α]D
20 +52.1 (c 1.1, acetone). Data
for α- and β-14: IR (Si) νmax 3072, 2933, 2859, 1750, 1428, 1371, 1221,
1113, 1065, 1008 cm
 1;
1H NMR (400.1 MHz, CDCl3) δ (α-14) 7.67
(m, 6H),7.38 (m, 9H), 6.19 (s, 1H), 5.37 (dd, J= 4.8, 1.0 Hz, 1H),5.20
(d,J=1.0Hz,1H),4.24(td,J=4.8,4.0Hz,1H),3.84(ABsystem,JAB=
11.1Hz,JAX=JBX=4.0Hz,2H),2.10(s,3H),2.09(s,3H),2.03(s,3H),
1.06 (s, 9H); (β-14) 7.67 (m, 6H), 7.38 (m, 9H), 6.36 (d, J = 4.8 Hz,
1H), 5.62 (dd, J = 7.1, 6.0 Hz, 1H), 5.34 (dd, J = 7.1, 4.8 Hz, 1H), 4.12
(td, J= 6.0, 5.3 Hz, 1H), 3.81 (AB system, JAB= 11.0 Hz, JAX =JBX = 5.3
Hz,2H),2.06(s,3H),2.05(s,3H),1.88(s,3H),1.06(s,9H);
13CNMR
(100.6MHz,CDCl3)δ(α-14)169.8,169.6,169.3,135.61(2C),135.59
(2C), 133.1, 133.0, 129.7 (2C), 127.7 (4C), 99.6, 84.8, 81.4, 76.7, 62.7,
26.7(3C),21.0,20.7,20.6,19.3;(β-14)169.9,169.8,169.4,135.6(2C),
135.5 (2C), 133.2, 132.9, 129.8 (2C), 127.7 (4C), 93.6, 81.6, 75.6, 74.1,
64.3, 26.7 (3C), 20.9, 20.8, 20.4, 19.2. Anal. Calcd for C27H34O8Si: C,
63.01; H, 6.66. Found for crystalline α-14: C, 62.36; H, 6.84.
1-α-[20,30-Di-O-acetyl-50-O-(tert-butyldiphenylsilyl)-D-ara-
binofuranosyl]-2-nitroimidazole (α-15). A solution of α- and β-
14 (0.548 g, 1.06 mmol) in dry CH3CN (3 mL) was added to
2-nitroimidazole(0.113g,1mmol)triethylsilylatedaccordingtogeneral
procedure A under argon in dry CH3CN (5 mL). After the stirred
mixture was cooled to  20 C, TfOTES (1 mL, 1 M in dry 1,2-
C2H4Cl2)wasadded,andstirringwascontinuedfor3hat 8C(TLC,
hexanes/EtOAc, 2:1).Asaturated aqsolution ofNaHCO3(10mL)was
added, and the mixture was extracted with EtOAc (3   10 mL). The
combined organic layers were washed with water (10 mL), dried
(Na2SO4), and concentrated under reduced pressure. The residue was
purified by flash chromatography (hexanes/EtOAc, 2:1, Rf 0.21) to give
protected nucleoside α-15 (0.435 g, 72%) as a yellow oil (lit.
25 mp
53 C): [α]D
20 +21.3 (c 1.1, acetone); the
1H NMR data agree with
those of the literature;
25 IR (Si) νmax 2932, 2859, 1755, 1540, 1475,
1428, 1369, 1230, 1106 cm
 1;
13C NMR (100.6 MHz, CDCl3) δ 169.2,
168.9,144.2,135.64(2C),135.56(2C),132.8,132.7,130.0(2C),128.5,
127.8 (2C), 127.5 (2C), 121.9, 92.6, 87.4, 81.8, 76.8, 63.6, 26.7 (3C),
20.6, 20.4, 19.2.
Preparation of α- and β-15 in 1,2-C2H4Cl2. A solution α- and
β-14(0.680 g, 1.32 mmol) indry1,2-C2H4Cl2(4mL)was added under
argon at rt to 2-nitroimidazole (0.150 g, 1.32 mmol) trimethylsilylated
according to general procedure A, followed by TfOTMS (1.32 mL,
0.5 M in dry 1,2-C2H4Cl2). After the mixture was stirred for 4 h at rt,
CH2Cl2(20mL)andasaturatedaqsolutionofNaHCO3(20mL)were
added. The organic phase was separated, and the aqueous one was
extracted withCH2Cl2(3 10mL).Thecombinedorganiclayers were
dried (Na2SO4) and concentrated under reduced pressure. The residue
was purified by flash chromatography (hexanes/EtOAc, 3:1 and then
1:2; TLC, 2:1, Rf 0.21 for α-15 and 0.43 for β-15) to give recovered
startingmaterial(0.306g,45%),β-15(0.098g,13%),andα-15(0.122g,
16%).
1,2,3-Tri-O-acetyl-5-O-(tert-butyldiphenylsilyl)-α- and Tri-
O-acetyl-5-O-(tert-butyldiphenylsilyl)-β-D-ribofuranose (α-
and β-17). D-Ribose (0.751 g, 5 mmol) was silylated, acetylated, and
worked up in the same way as D-arabinose, except that the acetylation
was performed for 6 h at 60 C. The crude product (α:β = 1:0.9) was
purified by flash chromatography (hexanes/EtOAc, 3:1, Rf 0.73 for β-
anomer and 0.58 for α-anomer, hexanes/EtOAc, 2:1) to give β-
triacetate β-17 (0.720 g, 28%; 10 15% of it was unknown compounds)
and α-triacetate α-17 (0.849 g, 33%; 6% of it was an impurity) as
colorless, very viscous oils. Data forβ-17:[ α]D
20 +2.17 (c1.15, acetone);8164 dx.doi.org/10.1021/jo200727k |J. Org. Chem. 2011, 76, 8159–8167
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IR (Si) νmax 3050, 2933, 2859, 1 754, 1429, 1371, 1221, 1113,
1029 cm
 1;
1H NMR (400.1 MHz, CDCl3) δ 7.67 7.63 (m, 4H),
7.41 7.35 (m, 6H), 6.17 (d, J = 1.5 Hz, 1H), 5.55 (dd, J = 6.3, 4.8 Hz,
1H), 5.43 (dd, J = 4.8, 1.5 Hz, 1H), 4.24 (dt, J = 6.3, 3.5 Hz, 1H), 3.76
(ABsystem,JAX=JBX=3.5Hz,JAB=11.3Hz,2H),2.10(s,3H),2.03(s,
3H),1.93(s,3H),1.05(s,9H);
13CNMR(100.6MHz,CDCl3)δ169.7,
169.48, 169.46, 135.60 (2C), 135.5 (2C), 133.0, 132.80, 129.84, 129.8,
127.8(2C),127.7(2C),98.2,82.3,74.5,70.6,63.2,26.7(3C),20.9,20.5,
20.5, 19.2. Anal. Calcd for C27H34O8Si: C, 63.01; H, 6.66. Found: C,
63.29; H, 6.78. Data for α-17:[ α]D
20 +46.3 (c 1.2, acetone); IR (Si) νmax
3072, 2933, 2859, 1749, 1472, 1428, 1370, 1222, 1113, 1074, 1051,
1011 cm
 1;
1H NMR (400.1 MHz, CDCl3) δ 7.68 7.63 (m, 4H),
7.45 7.35 (m, 6H), 6.46 (d, J = 4.5 Hz, 1H), 5.50 (dd, J = 6.3, 2.0 Hz,
1H),5.41(dd,J=6.3,4.5Hz,1H),4.29(∼q,J≈2.5 Hz,1H),3.79(AB
system,J=11.5,3.0,2.3Hz,2H),2.11(s,3H),2.10(s,3H),2.07(s,3H),
1.05(s,9H);
13CNMR100.6MHz,CDCl3)δ170.2,169.9,169.3,135.6
(2C), 135.6 (2C), 132.8, 132.6, 130.3, 130.2, 127.8 (2C), 127.8 (2C),
94.5, 85.0, 70.6, 70.5, 63.4, 26.7 (3C), 21.1, 20.7, 20.3, 19.2.
1-β-[20,30-Di-O-acetyl-50-O-(tert-butyldiphenylsilyl)-D-
ribofuranosyl]-2-nitroimidazole (β-18). A solution of β-17
(0.395 g, 0.77 mmol) in dry CH3CN (3 mL) was added to 2-nitroimi-
dazole (0.087 g, 0.77 mmol) triethylsilylated according to general
procedure A in dry CH3CN (2 mL) under argon. After the stirred
mixture was cooled to  20 C, TESOTf (0.77 mL, 1 M in dry 1,2-
C2H4Cl2) was added, and stirring was continued for 2 h while the
temperature of the reaction mixture was allowed to slowly rise to 8 C
in the cooling bath (TLC, hexanes/EtOAc, 2:1). Saturated aq NaHCO3
(10 mL) was added, and the mixture was extracted with EtOAc (3  
10 mL).Thecombinedorganiclayers werewashedwith water(10mL),
dried (Na2SO4),and concentrated under reduced pressure. Theresidue
was purified by flash chromatography (hexanes/EtOAc, 3:1, Rf 0.47 for
2:1) to give nucleoside β-18
18 (0.315 g, 72%) as yellow crystals; a trace
of possibly α-anomer was detected by TLC: [α]D
20 +13.31 (c 1.3,
acetone); mp 130 131 C (CHCl3/i-Pr2O) (lit.
18 mp 52 53 C).
Similarly, triacetate α-17 (0.395 g, 0.77 mmol) was reacted in the
same way, except that the temperature was allowed to warm to rt within
2 h, and yielded (0.381 g, 87%) β-18; a trace of possibly α-18 could be
detected in the crude product by TLC: IR (Si) νmax 2932, 1755, 1589,
1542, 1477, 1428, 1369, 1238, 1114, 1081, 1011 cm
 1; the
1H and
13C
NMR data agree with those of the literature.
18 Anal. Calcd for
C28H33N3O8Si: C, 59.24; H, 5.86; N, 7.40. Found: C, 58.98; H, 5.56;
N, 7.14.
1-β- and 1-α-(20,30,5-Tri-O-benzoyl-D-ribofuranosyl)-2-ni-
troimidazole (β- and α-20). A solution of 1-O-acetyl-2,3,5-tri-O-
benzoyl-β-D-ribofuranose(0.605 g, 1.2 mmol,1.2 equiv) in dryCH3CN
(4.6 mL) was added to the stirred mixture of 2-nitroimidazole (0.113 g,
1.0 mmol; triethylsilylated according to general procedure A) in dry
CH3CN (5.0 mL) under argon. TMSOTf (0.5 M, 2.4 mL, in dry
CH2Cl2) was added, and stirring was continued at rt (23 C) for 1 h
(TLC, hexanes/EtOAc, 2:1). A saturated aq solution of NaHCO3
(10 mL) was added, and the mixture was extracted with EtOAc (3  
10 mL). The combined organic layers were dried (Na2SO4) and
concentrated under reduced pressure. The residue was purified by flash
chromatography (hexanes/EtOAc, 2:1; β-20, Rf 0.38; α-20, Rf 0.26) to
yield β-20 (0.173 g, 31%) as a yellow oil and α-20 (0.235 g, 42%) as
yellow crystals: mp 136 138 C (CHCl3/i-Pr2O) [lit.
19 mp 138.5 
140 C (CH2Cl2/MeOH)]. Data for β-20:[ α]D
20 +27.47 (c 0.91,
acetone); IR (Si) νmax 1733, 1541, 1479, 1452, 1366, 1268, 1118,
1094,1071cm
 1;
1HNMR(400.1MHz,CDCl3)δ8.09 8.05(m,2H),
7.99 7.95(m,2H),δ7.91 7.87(m,2H),7.64 7.51(m,3H),7.57(d,
J=1.3Hz,1H),7.50 7.44(m,2H),7.43 7.38(m,2H),7.37 7.32(m,
2H),7.12(d,J=1.3Hz,1H),6.97(d,J=4.0Hz,1H),5.86(t,J=5.6Hz,
1H), 5.82 (dd, J = 5.6, 4.0 Hz, 1H), 4.86 (dd, J = 12.4, 2.7 Hz, 1H), 4.83
(∼td,J=5.6,3.5,2.7Hz,1H),4.70(dd,J=12.4,3.5Hz,1H);
13CNMR
(100.6 MHz, CDCl3) δ 166.0, 165.2, 164.8, 144.4 (br), 133.9, 133.9,
133.7, 129.9 (2C), 129.8 (2C), 129.7 (2C), 129.1, 129.1, 128.8 (2C),
128.6 (2C), 128.6 (2C), 128.3, 128.3, 121.5, 89.6, 80.7, 76.1, 70.2, 63.0.
Data for α-20:[ α]D
20  56.8 (c 1.07, acetone); IR (Si) νmax 1732, 1539,
1479, 1452,1365,1267,1095, 1070,1026cm
 1;
1HNMR(400.1MHz,
CDCl3)δ8.14 8.09(m,2H),7.71 7.67(m,2H),7.64 7.56(m,3H),
7.54 7.46 (m, 5H), 7.34 7.27 (m, 4H), 7.23 (d, J = 1.3 Hz, 1H), 7.16
(d,J=5.6Hz,1H),6.30(t,J=5.6Hz,1H),5.92(dd,J=5.6,3.2Hz,1H),
5.06(ddd≈q,J=3.4Hz,1H),4.79(dd,J=12.4,3.4Hz,1H),4.63(dd,
J = 12.4, 3.4 Hz, 1H);
13C NMR (100.6 MHz, CDCl3) δ 165.9, 165.0,
164.0, 144.6, 133.9, 133.8, 133.6, 129.7 (2C), 129.6 (2C), 129.4 (2C),
129.0, 128.7 (2C), 128.6 (2C), 128.5 (2C), 128.2, 128.2, 127.7, 122.5,
88.1, 82.7, 71.8, 71.3, 63.9.
1-β-(20,30,40,60-Tetra-O-acetyl-D-galactopyranosyl)-2-ni-
troimidazole (β-22). A solution of 1,2,3,4,6-penta-O-acetyl-β-D-
galactopyranose (1.171 g, 3 mmol) in dry CH3CN (20 mL) was added
to the mixture of 2-nitroimidazole (0.339 g, 3.0 mmol; triethylsilylated
according to general procedure A) in dry CH3CN (4 mL, sonicated for
2 min) under argon. After the stirred mixture was cooled to 0 C,
TfOTES (3.6 mL, 1.2 equiv, 1 M in dry 1,2-C2H4Cl2) was added, and
stirringwascontinuedfor1hat0Cand1hatrt.Asaturatedaqsolution
of NaHCO3 (20 mL) was added ,and the mixture was extracted with
EtOAc (3   15 mL). The combined organic layers were washed with
water (20 mL), dried (Na2SO4), and concentrated under reduced
pressure. The residue was purified by flash column chromatography
(hexanes/EtOAc, 2:1; TLC, hexanes/EtOAc, 1:1, Rf 0.45) to give
nucleoside β-22
21a (1.219 g, 92%) as a gum: [α]D
20 +62.50 (c 1.48,
acetone); IR (Si) νmax 1753, 1370, 1231,1094, 1064 cm
 1;
1H NMR
(400.1MHz,CDCl3)δ7.41(d,J=1.0Hz,1H),7.16(d,J=1.0Hz,1H),
6.38(d,J=9.1Hz,1H),5.51(dd,J=3.3,1.0Hz,1H),5.44(dd,J=10.1,
9.1 Hz, 1H), 5.33 (dd, J = 10.1, 3.3 Hz, 1H), 4.25 (ddd, J = 7.1, 5.8, 1.0
Hz, 1H), 4.14 (AB system, J = 11.4, 7.1, 5.8 Hz, 2H), 2.17 (s, 3H), 2.01
(s, 3H), 1.96 (s, 3H), 1.88 (s, 3H);
13C NMR (100.6 MHz, CDCl3) δ
170.3,169.8,169.6,169.1,144.5,128.9,122.1,83.5,74.2,70.9,68.7,67.0,
61.1, 20.5 (2C), 20.4, 20.2.
1-α-(20,30-Di-O-acetyl-D-arabinofuranosyl)-2-nitroimida-
zole(α-23).Nucleosideα-15(0.231g,0.407mmol)wasdesilylatedby
general procedure B. The crude product was purified by flash chroma-
tography (at first hexanes/EtOAc, 1:1, Rf 0.08, and then 1:5) to give α-
23 (0.113 g, 84%) as a crystalline solid: mp 115 116 C( C 2H4Cl2/i-
Pr2O) (lit.
26 semisolid mass); [α]D
20  5.6 (c 1.1, acetone); IR (Si) νmax
3387,2939,1748,1539,1479,1371,1234,1161,1063cm
 1;
1Hand
13C
NMR data agree with those of the literature.
25
1-α-[20,30-Di-O-acetyl-50-O-(4-toluenesulfonyl)-D-ara-
binofuranosyl]-2-nitroimidazole (α-7). α-23 (0.300 g, 0.91
mmol) was tosylated by general procedure C. The crude product was
purified by flash chromatography (hexanes/EtOAc, 1:1, Rf 0.26) to give
tosylate α-7 (0.420 g, 95%) as colorless plates: mp 102 103 C
(CHCl3/i-Pr2O); [α]D
20 +39.3 (c 0.9, acetone);
28 IR (Si) νmax 1750,
1540, 1477, 1368, 1232, 1191, 1178, 1096, 1052 cm
 1; the
1H and
13C
NMR data agree with those of the literature, except that a signal in the
13C NMR spectrum at 20.4 is replaced by one at 17.3.
28
1-β-a n d1 - α-[1,2-Di-O-acetyl-3,5-O,O-(1,1,3,3-tetra-
isopropyldisiloxanylidene)-D-ribofuranose (β- and α-24). D-
Ribose (0.45 g, 3 mmol) was dissolved in dry pyridine (15 mL) under
argon and cooled to  35 C. 1,3-Dichloro-1,1,3,3-tetraisopropyldisi-
loxane (0.946, 0.96 mL) was added, and the mixture was stirred and
allowed to slowly warm in the cooling bath to rt (18 h). Ac2O (1.5 mL)
was added, and stirring was continued for another 6 h, before water
(2 mL) was added. After 10 min the mixture was concentrated under
reduced pressure. The residue was treated with water (20 mL) and
EtOAc (20 mL). The organic phase was separated, and the aq one was
extraceted with EtOAc (15 mL). The combined organic layers were
washed (20 mL each) with water, 2 N HCl, water, and a saturated aq8165 dx.doi.org/10.1021/jo200727k |J. Org. Chem. 2011, 76, 8159–8167
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solution of NaHCO3, dried (Na2SO4), and concetrated under reduced
pressure. The residue was purified by flash column chromatography
(hexanes/EtOAc, 10:1; TLC, Rf 0.31 for 7:1) to yield a seemingly
homogeneous oily product [0.670 g, 47%; by
1H NMR a mixture of α-
anomer (δ 5.93, J = 7.9 Hz):β-anomer (δ 6.03, J = 0 Hz):unknown
compound (δ 6.09, J = 4.1 Hz) = 74:19:7], [α]D
20  35.81 (c 1.55,
acetone), in which gradually crystals of the α-anomer formed. Hexanes
wereadded,andthemixturewasstoredat 18C.Thecolorlessneedles
were collected and recrystallized (hexanes,  18 C). Data for α-24:m p
69 70 C (hexanes,  18 C); [α]D
20  39.75 (c 1.2, acetone); IR (Si)
νmax2946, 2868, 1747,1464, 1373,1216, 1169, 1125,1078, 1010cm
 1;
1H NMR (400.1 MHz, CDCl3) δ 5.93 (d, J = 7.9 Hz, 1H), 4.80 (dd, J =
7.9,2.8Hz,1H),4.57(dd≈t,J=2.8,2.3Hz,1H),4.10(ddd,J=9.6,5.2,
2.3Hz,1H),3.79(ABpartofABXsystem,J=11.0,9.6,5.2Hz,2H),2.07
(s, 3H), 2.06 (s, 3H), 1.09 0.82 (m, 28H);
13C NMR (100.6 MHz,
CDCl3)δ169.9,169.4,90.3,71.1,70.5,70.5,64.6,21.0,20.9,17.4(2C),
17.2(2C),17.2(2C),17.14,17.09,14.0,13.6,13.0,12.6.Anal.Calcdfor
C21H40O8Si2: C, 52.91; H, 8.46. Found: C, 52.64; H, 8.38.
1-β- and 1-α-[20-O-Acetyl-30,50-O,O-(1,1,3,3-tetraisoprop-
yldisiloxanylidene)-D-ribofuranosyl]-2-nitroimidazole
(β- and α-25). A solution of α- and β-24 (0.634 g, 1.33 mmol) in dry
CH3CN (5 mL) was added to 2-nitroimidazole (0.107 g, 0.95 mmol)
triethylsilylatedaccordingtogeneralprocedureAindryCH3CN(2mL)
under argon. After the stirred mixture was cooled to 0 C, TfOTES
(1.14 mL, 1 M solution in dry 1,2-C2H4Cl2) was added dropwise, and
stirring was continued for 45 min at that temperature. Then a saturated
aq solution of NaHCO3 (10 mL) was added, and the mixture was
extracted with EtOAc (3   15 mL). The combined organic layers were
dried (Na2SO4) and concentrated under reduced pressure. The residue
was flash chromatographed (hexanes/EtOAc, 5:1; β-25, Rf 0.36; α-25,
Rf 0.21) to yield nucleosides β-25 (0.152 g, 30%) and α-25 (0.158 g,
32%), bothcolorless needles.Whenthereaction mixturewas allowedto
warmfrom 10Cto rt,theβ-andα-anomerswereformed inyieldsof
16% and 32%, respectively. Data for β-25: mp 143 144 C( i-Pr2O/
hexanes); [α]D
20 +4.06 (c 0.91, acetone); IR (Si) νmax 2946, 2868, 1764,
1543,1474, 1370,1231,1116,1073, 1040cm
 1;
1HNMR(400.1MHz,
CDCl3)δ7.77(d,J=1.0Hz,1H),7.14(d,J=1.0Hz,1H),6.34(s,1H),
5.46 (d, J = 4.8 Hz, 1H), 4.43 (dd, J = 9.4, 4.8 Hz, 1H), 4.28 (d, J = 13.6
Hz, 1H), 4.10 (dd, J = 9.4, 2.5 Hz, 1H), 4.00 (dd, J = 13.6, 2.5 Hz, 1H),
2.17 (s, 3H), 1.11 0.83 (m, 28H);
13C NMR (100.6 MHz, CDCl3) δ
168.5, 143.7, 128.5, 122.3, 91.0, 82.6, 72.3, 66.8, 59.3, 20.5, 17.4, 17.3,
17.2, 17.2, 16.9, 16.8, 16.70, 16.66, 13.4, 12.9, 12.8, 12.6. Anal. Calcd for
C22H39N3O8Si2:C,49.88;H,7.42;N,7.93.Found:C,49.48;H,7.61;N,
7.83.Dataforα-25:mp106 107C(i-Pr2O/hexanes);[α]D
20+43.78(c
0.95, acetone); IR (Si) νmax 2946, 2868, 1748, 1545, 1484, 1374, 1225,
1169, 1117, 1053, 1033, 1009 cm
 1;
1H NMR (400.1 MHz, CDCl3) δ
7.26(d,J=1.3Hz,1H),7.11(d,J=1.3Hz,1H),6.70(d,J=9.1Hz,1H),
4.86 (dd, J = 9.1, 2.3 Hz, 1H), 4.65 (t, J = 2.3 Hz, 1H), 4.22 (td, J = 8.3,
2.3Hz,1H),3.92(d,J=8.3Hz,2H),1.88(s,3H),1.15 0.82(m,28H);
13C NMR (100.6 MHz, CDCl3) δ 169.5, 144.9, 128.7, 121.3, 80.7, 72.4,
71.2,70.6, 66.5,20.4,17.41,17.37,17.22,17.16,17.1(2C),17.06,17.02,
14.1,13.7,12.9,12.8.Anal.CalcdforC22H39N3O8Si2:C,49.88;H,7.42;
N, 7.93. Found: C, 49.74; H, 7.40; N, 7.88.
1-β-[20,30-Di-O-acetyl-D-ribofuranosyl]-2-nitroimidazole
(β-26). Nucleoside β-18 (0.381 g, 0.67 mmol) was desilylated by
general procedure B. The crude product was purified by flash chroma-
tography (starting with hexanes/EtOAc, 1:1, Rf 0.18, and then hexanes/
EtOAc,1:5)togivealcoholβ-26
18(0.158g,71%)asyellowcrystals:mp
125 126 C (1,2-C2H4Cl2/i-Pr2O) (lit.
18 mp 122 123 C); [α]D
20
+29.82 (c 1.1, acetone); IR (Si) νmax 3374, 3121, 2937, 1750, 1541,
1483, 1430, 1367, 1243, 1161, 1101, 1079, 1013 cm
 1; the
1H and
13C
NMR data are identical to those of the literature.
18 Anal. Calcd for
C12H15N3O8: C, 43.77; H, 4.59; N, 12.76. Found: C, 43.86; H, 4.42;
N, 12.73.
1-β-[20,30-Di-O-acetyl-50-O-(4-toluenesulfonyl)-D-ribofu-
ranosyl]-2-nitroimidazole (β-27). A solution of 4-toluenesulfonyl
chloride (0.173 g, 0.91 mmol, 3 equiv) and alcohol β-26 (0.100 g, 0.304
mmol) in dry pyridine (2 mL) was kept for 18 h at 4 C. When the
starting alcohol was consumed (TLC, hexanes/EtOAc, 1:1), water
(10 mL) and 2 M HCl (10 mL) were added. The mixture was extracted
with EtOAc (3   10 mL). The combined organic layers were washed
with saturated aq NaHCO3 (10 mL) and water (10 mL), dried
(Na2SO4), and concentrated under reduced pressure. The residue was
purified by flash chromatography (hexanes/EtOAc, 1:1, Rf = 0.41) to
give tosylate β-27 (0.102 g, 69%) as a yellow foam: [α]D
20 +44.2 (c 1.0,
acetone); IR (Si) νmax 1755, 1542, 1478, 1368, 1239, 1191, 1178,
1096cm
 1;
1HNMR(400.1MHz,CDCl3)δ7.79 (m,2H),7.49(d,J=
1.1 Hz, 1H), 7.36 (m, 2H), 7.12 (d, J = 1.1 Hz, 1H), 6.59 (d, J = 3.8 Hz,
1H), 5.38 (dd, J = 5.6, 3.8 Hz, 1H), 5.23 (dd ≈ t, J = 6.1, 5.6 Hz, 1H),
4.44(dd,J=11.4,2.4Hz,1H),4.38(dt,J=6.1,2.3Hz,1H),4.22(dd,J=
11.4, 2.3 Hz, 1H), 2.44 (s, 3H), 2.10 (s, 3H), 2.03 (s, 3H);
13C NMR
(100.6 MHz, CDCl3) δ 169.2, 168.9, 145.7, 144.2, 132.0, 130.2 (2C),
129.1, 128.0 (2C), 121.7, 89.4, 79.6, 74.8, 68.7, 66.5, 21.7, 20.3, 20.2.
Anal. Calcd for C19H21N3O10S: C, 47.20; H, 4.38; N, 8.69. Found: C,
47.48; H, 4.48; N, 8.48.
1-α-[50-O-(tert-Butyldiphenylsilyl)-D-ribofuranosyl]-2-ni-
troimidazole (α-30). A mixture of tribenzoate α-20 (0.398 g, 0.714
mmol)andMeONa/MeOH(3.0mL,0.05M)wasstirredat0C.When
the transesterification (TLC, hexanes/EtOAc, 1:2) was finished (2 h),
AcOH (3 drops) was added immediately, and the solvent was removed
under reduced pressure. The residue was purified by flash chromatog-
raphy (CHCl3/MeOH, 4:1, Rf 0.39) to yield an inseparable mixture of
α-28 and a side product (10 20%) with the tentatively assigned
structure 29 (0.132 g):
1H NMR (400.1 MHz, CD3OD) δ (α-28)
7.62 (s,1H), 7.13 (s,1H), 6.71 (d, J=4.8 Hz,1H), 4.61 (dd ≈t, J=5.3,
4.8 Hz, 1H), 4.31 (m, 1H), 3.84 (dd, J = 12.2, 2.8 Hz, 1H), 3.67 (dd, J =
12.2, 4.2 Hz, 1H); (29) 6.83 (s, 1H), 6.62 (s, 1H), 6.25 (d, J = 5.3 Hz,
1H), 5.56 (t, J = 5.3 Hz, 1H). TBDPSCl (0.412 g, 0.39 mL, 1.50 mmol)
was added to a solution of the mixture of α-28 and 29 (0.132 g) in dry
pyridine (2.5 mL), and the mixture was stirred at rt until the starting
material was consumed (2 h; TLC, CHCl3/MeOH, 4:1, for starting
material, hexanes/EtOAc, 1:1, for product α-30). The reaction was
quenched with water (10 mL) and 2 M HCl (10 mL), and the mixture
was extracted with EtOAc (3   10 mL). The combined organic layers
were washed with saturated aq NaHCO3 (10 mL) and water (10 mL),
dried (Na2SO4), and concentrated under reduced pressure. The crude
product was purified by flash chromatography (hexanes/EtOAc, 1:1, Rf
0.38) to give α-30 (0.179 g, 52%, starting from tribenzoate α-20): mp
150 151 C (EtOAc); [α]D
20  33.6 (c 1.22, EtOH); IR (ATR) νmax
3413, 3200, 2927, 1537, 1354, 1487, 1354, 1111, 1090, 1048,
1036 cm
 1;
1H NMR (400.1 MHz, DMSO-d6) δ 7.68 7.62 (m, 4H),
7.59 (s, 1H), 7.51 7.40 (m, 6H), 7.17 (s, 1H), 6.62 (d, J = 4.8 Hz, 1H),
5.49 (d, J = 5.8 Hz, 1H), 5.03 (d, J = 5.1 Hz, 1H), 4.55 4.49 (m, 1H),
4.34 (br s, 1H), 4.20 4.15 (m, 1H), 3.82 (AB system, J = 11.5, 3.7, 1.7
Hz, 2H), 1.03 (s, 9H);
13C NMR (100.61, DMSO-d6) δ 144.5, 135.1
(4C), 132.8, 132.7, 129.9 (2C), 128.0 (2C), 127.9 (2C), 127.1, 124.3,
89.9, 84.9, 71.0, 70.6, 63.8, 26.6 (3C), 18.8. Anal. Calcd for
C24H29N3O6Si: C, 59.61; H, 6.04; N, 8.69. Found: C, 59.62; H, 5.98;
N, 8.68.
1-α-[20,30-Di-O-acetyl-50-O-(tert-butyldiphenylsilyl)-D-
ribofuranosyl]-2-nitroimidazole (α-18). Ac2O (0.3 mL) was
added to a solution of diol α-30 (0.070 g, 0.145 mmol) in dry pyridine
(0.3 mL) and dry CHCl3 (2 mL). The mixture was heated and stirred
for 30 min at 50 C (TLC, hexanes/EtOAc, 1:1). After cooling, water
(5 mL) and 2 M HCl (5 mL) were added. The resulting mixture
was extracted with EtOAc (3   10 mL). The combined organic layers
were washed with saturated aq NaHCO3 (10 mL) and water (10 mL),
dried (Na2SO4), and concentrated under reduced pressure. The crude8166 dx.doi.org/10.1021/jo200727k |J. Org. Chem. 2011, 76, 8159–8167
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product was purified by flash chromatography (hexanes/EtOAc, 2:1,
Rf 0.56 for hexanes/EtOAc, 1:1) to give diacetate α-18 (0.074 g, 90%): mp
134 135 C( C H C l 3/i-Pr2O); [α]D
20  41.49 (c 0.4, acetone); IR (Si)
νmax 2932, 2859, 1753, 1539, 1478, 1367, 1233, 1105 cm
 1;
1HN M R
(400.1 MHz, CDCl3) δ 7.70 7.65 (m, 4H), 7.46 7.36 (m, 7H), 7.16 (d,
J=1.3Hz,1H),6.88(d,J=5.8Hz,1H),6.05(dd≈t,J=5.7Hz,1H),5.53
(dd,J= 5.3, 1.8 Hz, 1H), 4.54 (ddd ≈q,J= 2.1 Hz, 1H), 3.84 (AB system,
J = 11.6, 2.6, 2.3 Hz, 2H), 1.89 (s, 3H), 1.84 (s, 3H), 1.10 (s, 9H);
13C
NMR(100.6MHz,CDCl3)δ169.3,168.2,144.7,135.5(2C),135.5(2C),
132.2 (2C), 130.1, 130.0, 127.91 (2C), 127.90 (2C), 127.5, 122.4, 87.5,
85.6, 71.8, 71.1, 63.9, 26.7 (3C), 20.3, 19.7, 19.0. Anal. Calcd for
C28H33N3O8Si: C, 59.24; H, 5.86; N, 7.40. Found: C, 59.33; H, 5.59;
N, 7.42.
1-α-(20,30-Di-O-acetyl-D-ribofuranosyl)-2-nitroimidazole
(α-26). Nucleoside α-18 (0.194 g, 0.342 mmol) was desilylated by
general procedure B. The residue was purified by flash chromatography
(hexanes/EtOAc, 1:1, Rf 0.10) to give α-26 (0.102 g, 91%) as an oil:
[α]D
20  47.54 (c 1.3, acetone); IR (Si) νmax 3385, 1751, 1541, 1482,
1367,1240,1161,1104cm
 1;
1HNMR(400.1MHz,CDCl3)δ7.39(d,
J=1.1Hz,1H),7.17(d,J=1.1Hz,1H),6.90(d,J=5.5Hz,1H),5.87(t,
J = 5.5 Hz, 1H), 5.26 (dd, J = 5.5, 2.8 Hz, 1H), 4.56 (q, J = 2.8 Hz, 1H),
3.87(ABsystem,J=12.1,2 2.8Hz,2H),2.55(brs,1H),1.92(s,3H),
1.83 (s, 3H);
13C NMR (100.6 MHz, CDCl3) δ 169.6, 168.5, 144.6,
127.6, 122.5, 87.6, 85.2, 71.2, 71.0, 62.0, 20.3, 19.8. Anal. Calcd for
C12H15N3O8: C, 43.77; H, 4.59; N, 12.76. Found: C, 43.43; H, 4.26;
N, 12.17.
1-α-[20,30-Di-O-acetyl-50-O-(4-toluenesulfonyl)-D-ribofu-
ranosyl]-2-nitroimidazole(α-27).4-Toluenesulfonylchloride(0.136g,
0.693 mmol, 3 equiv) was dissolved in a solution of alcohol α-26 (0.076 g,
0.231 mmol) in dry pyridine (1.26 mL). The reaction mixture was kept for
18 h at 4 C (no starting material; TLC, hexanes/EtOAc, 1:2) and then
quenchedbyaddingwater(10mL) and2MHCl(10mL).Themixturewas
extracted with EtOAc (3   10 mL). The combined organic layers were
washed with saturated aq NaHCO3 (10 mL) and water (10 mL), dried
(Na2SO4), and concentrated under reduced pressure. The residue was
purified by flash chromatography (hexanes/EtOAc, 1:1, Rf 0.31 for hex-
anes/EtOAc, 1:2) to give tosylate α-27 (0.084 g, 75%): mp 119 120 C
(CHCl3/i-Pr2O); [α]D
20  18.87 (c 0.8, acetone); IR (Si) νmax 1756, 1539
1480,1367,1234,1178cm
 1;
1HNMR(400.1MHz,CDCl3)δ7.81(d,J=
8.3Hz, 2H), 7.35(d, J= 8.3Hz, 2H), 7.29(s, 1H), 7.14 (s, 1H), 6.62 (d, J=
5.3Hz,1H),5.68(t,J=5.3Hz,1H),5.28(dd,J=5.3,3.7Hz,1H),4.62(ddd
≈q,J=3.5Hz,1H),4.30(ABsystem,J=11.6,3.5,3.0Hz,2H),2.42(s,3H),
1.90 (s, 3H), 1.82 (s, 3H);
13C NMR (100.6 MHz, CDCl3) δ 169.1, 168.0,
145.7, 144.5, 132.3, 130.1 (2C), 127.9 (2C), 127.8, 122.2, 87.5, 81.6, 70.5,
70.4,68.0,21.6,20.2,19.7.Anal.Calcd.forC19H21N3O10S:C,47.20;H,4.38;
N, 8.69. Found: C, 46.93; H, 4.14; N, 8.50.
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